Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIERRA: Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma
NCT05883644Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Incidence of grade 3 or 4 possibly related to treatment adverse events at 6 months and Objective response rate up to 33 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05883644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05883644.